(Press-News.org) A study led by the researcher at the Institute of Biomedical Research (IDIBELL), Isabel Fabregat, could serve to select patients with hepatocellular carcinoma unresponsive to most frequently used drug in liver cancer: sorafenib. The study, published in the International Journal of Cancer describes how tumor cells that have a less differentiated phenotype (mesenchymal) and expresses CD44, do not respond to Sorafenib action.
Difficult treatment
Hepatocellular carcinoma is one of the cancers with the worst prognosis and more difficult treatment. Surgery is only possible when the tumor is well located and the protocol for liver transplantation requires specific requirements for number and size of tumor nodules.
However, there is a drug used in advanced stages of hepatocellular carcinoma: Sorafenib. It is a tyrosine kinase inhibitor which has an extremely specific action. As explained Isabel Fabregat "Sorafenib could act not only on tumor cells by inhibiting the growth and inducing cell death but also on cells accompanying the tumor, the stroma, by their ability to inhibit the formation of blood vessels to provide nutrients to the tumor cells. Sorafenib treatment induces a delay in tumor process but generally fails to produce the patient's recovery. "
Therefore, many laboratories are currently working on the study of the action of this drug to improve therapy either attaching different drugs or selecting patients.
In this sense, the study of the research group in Biological Keys Invasive and Metastatic Phenotype led by Fabregat analyzed the phenotypic and molecular characteristics of several cell lines and in animal models and their response to Sorafenib.
Resistence biomarkers
"We have observed that the cells which exhibit a mesenchymal phenotype (where the tumor cells are less differentiated and are potentially more aggressive) and which express CD44, a marker of tumor-initiating cells, are resistant to Sorafenib".
The study proposes CD44 as a potential marker that could be used clinically to select patients who will not respond to treatment and thus spare them the side effects.
"Moreover," says Fabregat "the proposal of this paper is twofold. Also opens the door to designing joint therapies with Sorafenib and CD44 inhibitors as we have shown that genetic inhibition of this marker in
INFORMATION:
Fernando J., Malfettone A., Cepeda EB, Vilarrasa-Blasi R., Bertran E., Raimondi G., Fabra A., Alvarez-Barrientos A., Fernández-Salguero P., Fernández-Rodríguez CM, Giannelli G., Sancho P., Fabregat I. A mesenchymal-like Phenotype and expression of CD44 PREDICT lack of apoptótica response to sorafenib in liver tumor cells. International Journal of Cancer 2014 Jul 23 doi: 10.1002 / ijc.29097. [Epub ahead of print]
This news release is available in German. Bio-engineers are working on the development of biological computers with the aim of designing small circuits made from biological material that can be integrated into cells to change their functions. In the future, such developments could enable cancer cells to be reprogrammed, thereby preventing them from dividing at an uncontrollable rate. Stem cells could likewise be reprogrammed into differentiated organ cells.
The researchers have not progressed that far yet. Although they have spent the past 20 years developing individual ...
Scientists at the University of Manchester, King's College London and the University of Liverpool have found that an infant's preference for a person's face, rather than an object, is associated with lower levels of callous and unemotional behaviors in toddlerhood.
The study, which was published in Biological Psychiatry, assessed if 213 five-week-old infants spent longer tracking a person's face compared to an inanimate object – in this case a red ball.
The researchers showed that greater tracking of the face relative to the ball was linked to lower callous unemotional ...
This news release is available in Spanish.
Martín Olazar, a UPV/EHU chemical engineer, has designed a fundamental process for producing alternatives to petroleum in sustainable refineries. As Olazar himself pointed out, one of the unavoidable conditions of the process is not to harm the environment. This researcher has developed a reactor based on conical spouted beds which, by means of flash or rapid pyrolysis, produces fuels and raw materials using various types of waste.
Olazar has developed two lines, depending on the type of waste: one uses biomass; the ...
The average U.S. doctor spends 16.6 percent of his or her working hours on non-patient-related paperwork, time that might otherwise be spent caring for patients. And the more time doctors spend on such bureaucratic tasks, the unhappier they are about having chosen medicine as a career.
These are some of the findings of a nationwide study by Drs. Steffie Woolhandler and David Himmelstein, internists in the South Bronx who serve as professors of public health at the City University of New York and lecturers in medicine at Harvard Medical School. The study was published ...
MANHATTAN, Kansas — Football teams are claiming it improves their athletic performance, and according to new research from Kansas State University, it also benefits heart failure patients. The special ingredient: beetroot.
Recently, the Auburn University football team revealed its pregame ritual of taking beetroot concentrate, or beet juice, before each game. The juice may have contributed to the team's recent winning season — and one exercise physiologist who has been studying the supplement for several years says that may be the case.
"Our research, published ...
Scientists have identified 181 California dams that may need to increase water flows to protect native fish downstream. The screening tool developed by the Center for Watershed Sciences at the University of California, Davis, to select "high-priority" dams may be particularly useful during drought years amid competing demands for water.
"It is unpopular in many circles to talk about providing more water for fish during this drought, but to the extent we care about not driving native fish to extinction, we need a strategy to keep our rivers flowing below dams," said lead ...
Future prevention and treatment strategies for vascular diseases may lie in the evaluation of early brain imaging tests long before heart attacks or strokes occur, according to a systematic review conducted by a team of cardiologists, neuroscientists, and psychiatrists from Icahn School of Medicine at Mount Sinai and published in the October issue of JACC Cardiovascular Imaging.
For the review, Mount Sinai researchers examined all relevant brain imaging studies conducted over the last 33 years. They looked at studies that used every available brain imaging modality in ...
No-till farming, a key conservation agriculture strategy that avoids conventional plowing and otherwise disturbing the soil, may not bring a hoped-for boost in crop yields in much of the world, according to an extensive new meta-analysis by an international team led by the University of California, Davis.
As the core principle of conservation agriculture, no-till has been promoted worldwide in an effort to sustainably meet global food demand. But after examining results from 610 peer-reviewed studies, the researchers found that no-till often leads to yield declines compared ...
University of Southampton scientists have designed a new experiment to test the foundations of quantum mechanics at the large scale.
Standard quantum theory places no limit on particle size and current experiments use larger and larger particles, which exhibit wave-like behaviour. However, at these masses experiments begin to probe extensions to standard quantum mechanics, which describe the apparent quantum-to-classical transition.
Now, Southampton researchers, with colleagues from the University of Duisburg-Essen in Germany, have designed a new type of experiment ...
Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the drug offers an added benefit over the appropriate comparator therapy in these patient groups. According to the findings, such an added benefit is not proven because the dossier contained no suitable data for any of the two ...
